Literature DB >> 30099592

A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts.

Omer Karadag1,2,3, Abdulsamet Erden4, Yelda Bilginer4, Seerapani Gopaluni5, Alper Sari4, Berkan Armagan4, Ihsan Ertenli4, Seza Ozen4, David Jayne5.   

Abstract

There is a need for better definition of polyarteritis nodosa (PAN) subphenotypes and the influence of ethnicity and geography. This study is aimed to study the demographic and clinical features of PAN cohorts from the UK and Turkey (TR) and to compare and contrast disease characteristics. A retrospective survey of databases from two vasculitis centres between 1990 and 2016 for PAN patients fulfilling the EMEA Vasculitis Classification algorithm. All paediatric-onset adult patients met the Ankara 2008 (EULAR/PReS endorsed) criteria for childhood PAN. Those with typical angiographic and/or histopathologic findings consistent with PAN were included. 93 (M/F: 51/42) patients (UK: 47, TR: 46) were included. Three were HBV-related, 20 (21.5%) had paediatric onset and 16 (16.5%), cutaneous PAN. TR patients had younger age of disease onset 44 (28.5-59.0) vs. 24.5 (11.8-40.5), p = 0.002. Twelve (26%) of TR patients had monogenic disease (Familial Mediterranean Fever association (n = 7), deficiency of adenosine deaminase 2, DADA2, (n = 5). No difference was found in phenotype between paediatric and adult onset patients except for frequency of cutaneous lesions (p = 0.002). During a median 67.5 (32-126) months follow-up, 13 patients died (12.7% in UK vs. 15.2% in Turkish cohorts). No difference was found between two cohorts in relation to relapse rate, death and vasculitis damage index. This study defined a diagnosis of PAN according to the EMEA algorithm. The TR group had a younger age of disease onset and more cases of monogenic disease; however, disease extent, relapse rate, damage index and death rates were similar between groups.

Entities:  

Keywords:  Deficiency of adenosine deaminase 2 (DADA2); EMEA vasculitis classification; Familial Mediterranean Fever (FMF); Paediatric PAN; Polyarteritis nodosa (PAN); Vasculitis

Mesh:

Substances:

Year:  2018        PMID: 30099592     DOI: 10.1007/s00296-018-4122-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  22 in total

1.  ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).

Authors:  Anthea Craven; Joanna Robson; Cristina Ponte; Peter C Grayson; Ravi Suppiah; Andrew Judge; Richard Watts; Peter A Merkel; Raashid A Luqmani
Journal:  Clin Exp Nephrol       Date:  2013-08-31       Impact factor: 2.801

2.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

Review 3.  Treating polyarteritis nodosa: current state of the art.

Authors:  Mathilde de Menthon; Alfred Mahr
Journal:  Clin Exp Rheumatol       Date:  2011-05-11       Impact factor: 4.473

4.  Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.

Authors:  Loïc Guillevin; Alfred Mahr; Patrice Callard; Pascal Godmer; Christian Pagnoux; Emmanuelle Leray; Pascal Cohen
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

5.  Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series.

Authors:  Tanaz A Kermani; Erin K Ham; Michael J Camilleri; Kenneth J Warrington
Journal:  Semin Arthritis Rheum       Date:  2012-06-15       Impact factor: 5.532

6.  Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database.

Authors:  Christian Pagnoux; Raphaèle Seror; Corneliu Henegar; Alfred Mahr; Pascal Cohen; Véronique Le Guern; Boris Bienvenu; Luc Mouthon; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2010-02

7.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

Authors:  Richard Watts; Suzanne Lane; Thomas Hanslik; Thomas Hauser; Bernhard Hellmich; Wenche Koldingsnes; Alfred Mahr; Mårten Segelmark; Jan W Cohen-Tervaert; David Scott
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

8.  [Solitary liver tumor as a manifestation of polyarteritis nodosa].

Authors:  J Bohn; E Schippers; S Wagner; W Küsters; J Müller; M Meesmann; W Scheppach
Journal:  Dtsch Med Wochenschr       Date:  2010-02-02       Impact factor: 0.628

9.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients.

Authors:  L Guillevin; F Lhote; M Gayraud; P Cohen; B Jarrousse; O Lortholary; N Thibult; P Casassus
Journal:  Medicine (Baltimore)       Date:  1996-01       Impact factor: 1.889

10.  Polyarteritis nodosa complicating multiple myeloma - a case report and review of the literature.

Authors:  Markus Hutterer; Michael Steurer; Romana Höftberger; Johannes A Hainfellner; Andreas Pircher; Martha Nowosielski; Peter Hau; Wolfgang Löscher; Eberhard Gunsilius; Thomas Berger; Guenther Stockhammer
Journal:  Clin Neuropathol       Date:  2014 Mar-Apr       Impact factor: 1.368

View more
  2 in total

Review 1.  Clinical Approach to Diagnosis and Therapy of Polyarteritis Nodosa.

Authors:  Alojzija Hočevar; Matija Tomšič; Katja Perdan Pirkmajer
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

2.  Successful treatment of polyarteritis nodosa with intestinal necrosis in a Chinese boy: a case report.

Authors:  Rui Guo; Hongzhen Liu; Xiumei Liu; Wei Liu; Shisong Zhang
Journal:  Transl Pediatr       Date:  2022-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.